Related Experiment Video

Updated: Jul 19, 2026

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis

Christian T Brandt1, Niels Frimodt-Møller, Jens D Lundgren

  • 1National Center for Antimicrobials and Infection Control, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark. ctb@ssi.dk

The Journal of Antimicrobial Chemotherapy
|October 28, 2006
PubMed
Abstract

Insights

Administering anti-pneumococcal antiserum (APAS) with antibiotics at infection onset improved outcomes in a rat model of pneumococcal meningitis. However, APAS showed no benefit when given 26 hours post-infection, suggesting limited clinical value.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Bacteraemia accompanying meningitis significantly impacts patient prognosis.
  • Streptococcus pneumoniae is a leading cause of bacterial meningitis.

Purpose of the Study:

  • To evaluate the efficacy of serotype-specific anti-pneumococcal antiserum (APAS) in a rat model of pneumococcal meningitis.
  • To determine the optimal timing for APAS administration in conjunction with antibiotics.

Main Methods:

  • Rats were infected with Streptococcus pneumoniae serotype 3.
  • Ceftriaxone was administered 26 hours post-infection to all rats.
  • APAS was administered either at the time of infection or 26 hours post-infection and compared to antibiotic-only treatment.

Main Results:

  • A significant clinical benefit was observed when APAS was administered concurrently with infection.
  • No therapeutic effect was observed when APAS was administered 26 hours after infection.

Conclusions:

  • Early administration of APAS, alongside antibiotics, may offer clinical benefits in pneumococcal meningitis.
  • Delayed administration of APAS shows no added value, indicating its clinical utility may be restricted to early intervention.

More Related Videos

Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination09:11

Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination

Published on: September 25, 2014

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...